Home / RAD.AX : ASX

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does RAD.AX make money? Does RAD.AX have pricing power? What's the Earnings Whisper? Will RAD.AX profit more as the business scales? What is RAD.AX's management track record? Is RAD.AX's current price justified?

Radiopharm Theranostics Limited

AUD 0.01 -$0.02 (-72.00%)

ASX · 16 Sep 2026 03:00 UTC

Previous Close

AUD 0.01

Day Range

AUD 0.01AUD 0.01

Year Range

AUD 0.01AUD 0.04

Market Cap

16.55M

AVG Volume

5.67M

Trailing/Forward PE

-0.45/-

PEG ratio

0.12

Dividend Yield

Next Earnings Date

2027-02-26

Primary Exchange

Australian Securities Exchange

Revenue (AUD)

RAD.AX Revenue (AUD) by quarter
Period	Revenue (AUD)
26 Q4	1.38M
26 Q2	1.39M
25 Q4	10.96M
25 Q2	2.44M
24 Q4	299.23K
24 Q2	4.07M
23 Q4	973.99K
23 Q2	292.36K
22 Q4	-12
22 Q2	12

Net Income (AUD)

RAD.AX Net Income (AUD) by quarter
Period	Net Income (AUD)
26 Q4	-28.18M
26 Q2	-26.97M
25 Q4	-17.98M
25 Q2	-18.73M
24 Q4	-23.19M
24 Q2	-24.76M
23 Q4	-22.06M
23 Q2	-12.55M
22 Q4	-13.03M
22 Q2	-17.39M

Operating Income (AUD)

RAD.AX Operating Income (AUD) by quarter
Period	Operating Income (AUD)
26 Q4	-39.36M
26 Q2	-31.11M
25 Q4	-18.63M
25 Q2	-19.54M
24 Q4	-15.33M
24 Q2	-17.26M
23 Q4	-24.29M
23 Q2	-16M
22 Q4	-11.65M
22 Q2	-8.27M

EBITDA (AUD)

RAD.AX EBITDA (AUD) by quarter
Period	EBITDA (AUD)
26 Q4	-39.36M
26 Q2	-29.75M
25 Q4	-13.36M
25 Q2	-18.29M
24 Q4	-18.24M
24 Q2	-27.14M
23 Q4	-19.32M
23 Q2	-11.3M
22 Q4	-10.54M
22 Q2	-7.51M

Cash Flows (AUD)

RAD.AX Cash Flows (AUD) by quarter
Period	Cash Flows (AUD)
26 Q4	0
26 Q2	-22.67M
25 Q4	-14.43M
25 Q2	-22.22M
24 Q4	-11.2M
24 Q2	-11.77M
23 Q4	-12.62M
23 Q2	-12.11M
22 Q4	-5.64M
22 Q2	-32.6M

EPS (AUD)

RAD.AX EPS (AUD) by quarter
Period	EPS (AUD)
26 Q4	-0.01
26 Q2	-0.01
25 Q4	-0.01
25 Q2	-0.05
24 Q4	-0.06
24 Q2	-0.07
23 Q4	-0.06
23 Q2	-0.04
22 Q4	-0.05
22 Q2	-0.06

Expenses (AUD)

RAD.AX Expenses (AUD) by quarter
Period	Expenses (AUD)
26 Q4	9.41M
26 Q2	29.85M
25 Q4	23.42M
25 Q2	20.63M
24 Q4	14.08M
24 Q2	21.56M
23 Q4	21.01M
23 Q2	11.74M
22 Q4	10.59M
22 Q2	34.69M

Cash & Debt (AUD)

RAD.AX Cash & Debt (AUD) by quarter
Period	Cash & Debt (AUD)
26 Q4	4.14M
26 Q2	34.52M
25 Q4	29.12M
25 Q2	36.44M
24 Q4	18.58M
24 Q2	1.89M
23 Q4	26.98M
23 Q2	24.25M
22 Q4	26.98M
22 Q2	32.59M

Debt ratios

RAD.AX Debt ratios by quarter
Period	Debt ratios
26 Q4	0.04
26 Q2	0.43
25 Q4	0.38
25 Q2	0.44
24 Q4	0.24
24 Q2	0.03
23 Q4	0.55
23 Q2	0.82
22 Q4	1.46

Margins

RAD.AX Margins by quarter
Period	Margins
26 Q4	11.6%
26 Q2	-90.3%
25 Q4	205.94%
25 Q2	-523.95%
24 Q4	-7275.76%
24 Q2	-38.61%
23 Q4	-387.19%
23 Q2	-1482%
22 Q4	13483816.67%
22 Q2	-11361883.33%

Return on Capital

RAD.AX Return on Capital by quarter
Period	Return on Capital
26 Q4	-126.25%
26 Q2	-54%
25 Q4	-41.93%
25 Q2	-36.01%
24 Q4	-84.78%
24 Q2	-101.71%
23 Q4	-34.38%
23 Q2	-19.88%
22 Q4	-20.69%
22 Q2	-23.69%

Shares Outstanding

RAD.AX Shares Outstanding by quarter
Period	Shares Outstanding
26 Q4	3.52B
26 Q2	3.54B
25 Q4	2.33B
25 Q2	386.46M
24 Q4	364.87M
24 Q2	343.28M
23 Q4	359.27M
23 Q2	292.91M
22 Q4	279.77M
22 Q2	277.47M

Book Value Per Share (AUD)

RAD.AX Book Value Per Share (AUD) by quarter
Period	Book Value Per Share (AUD)
26 Q4	0.01
26 Q2	0.01
25 Q4	0.02
25 Q2	0.13
24 Q4	0.07
24 Q2	0.07
23 Q4	0.18
23 Q2	0.22
22 Q4	0.23
22 Q2	0.26

Total Assets (AUD)

RAD.AX Total Assets (AUD) by quarter
Period	Total Assets (AUD)
26 Q4	60.13M
26 Q2	91.17M
25 Q4	86.48M
25 Q2	92.45M
24 Q4	72.04M
24 Q2	63.29M
23 Q4	83.38M
23 Q2	85.07M
22 Q4	83.38M
22 Q2	91.05M

Free Cash Flow Yield

RAD.AX Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-248.72%
Sep 26	-248.72%
Sep 26	-221.08%
Aug 26	-221.08%
Aug 26	-198.97%
Aug 26	-180.89%
Aug 26	-165.81%
Jul 26	-142.12%
Jul 26	-104.72%
Jul 26	-99.49%
Jul 26	-104.72%
Jul 26	-99.49%
Jun 26	-104.72%
Jun 26	-99.49%
Jun 26	-99.49%
Jun 26	-99.49%
May 26	-99.49%
May 26	-94.75%
May 26	-94.75%
May 26	-104.72%
May 26	-104.72%
Apr 26	-99.49%
Apr 26	-99.49%
Apr 26	-90.44%
Apr 26	-94.75%
Mar 26	-127.67%
Mar 26	-127.67%
Mar 26	-116.06%
Mar 26	-121.59%
Feb 26	-111.02%
Feb 26	-116.06%
Feb 26	-116.06%
Feb 26	-121.59%
Jan 26	-121.59%
Jan 26	-111.02%
Jan 26	-102.14%
Jan 26	-102.14%
Jan 26	-102.14%
Dec 25	-94.57%
Dec 25	-98.21%
Dec 25	-134.39%
Dec 25	-116.06%
Nov 25	-116.06%
Nov 25	-121.59%
Nov 25	-116.06%
Nov 25	-111.02%
Oct 25	-106.39%
Oct 25	-98.21%
Oct 25	-69.01%
Oct 25	-69.01%
Oct 25	-77.38%
Sep 25	-515.87%
Sep 25	-482.58%
Sep 25	-482.58%
Sep 25	-534.29%
Aug 25	-534.29%
Aug 25	-554.08%
Aug 25	-575.39%
Aug 25	-623.34%
Aug 25	-650.44%
Jul 25	-650.44%
Jul 25	-680.01%
Jul 25	-680.01%
Jul 25	-650.44%
Jun 25	-680.01%
Jun 25	-623.34%
Jun 25	-575.39%
Jun 25	-598.4%
May 25	-623.34%
May 25	-712.39%
May 25	-680.01%
May 25	-712.39%
May 25	-650.44%
Apr 25	-712.39%
Apr 25	-680.01%
Apr 25	-650.44%
Apr 25	-650.44%
Mar 25	-484.27%
Mar 25	-466.98%
Mar 25	-466.98%
Mar 25	-435.85%
Feb 25	-502.9%
Feb 25	-544.81%
Feb 25	-523.01%
Feb 25	-523.01%
Jan 25	-523.01%
Jan 25	-484.27%
Jan 25	-466.98%
Jan 25	-373.58%
Jan 25	-523.01%
Dec 24	-568.49%
Dec 24	-544.81%
Dec 24	-450.87%
Dec 24	-421.79%
Nov 24	-466.98%
Nov 24	-523.01%
Nov 24	-523.01%
Nov 24	-544.81%
Nov 24	-544.81%
Oct 24	-502.9%

Price to Sales

RAD.AX Price to Sales by quarter
Period	Price to Sales
Sep 26	1.88
Sep 26	1.88
Sep 26	2.11
Aug 26	2.11
Aug 26	2.35
Aug 26	2.58
Aug 26	2.82
Jul 26	3.29
Jul 26	4.46
Jul 26	4.7
Jul 26	4.46
Jul 26	4.7
Jun 26	4.46
Jun 26	4.7
Jun 26	4.7
Jun 26	4.7
May 26	4.7
May 26	4.93
May 26	4.93
May 26	4.46
May 26	4.46
Apr 26	4.7
Apr 26	4.7
Apr 26	5.17
Apr 26	4.93
Mar 26	2.63
Mar 26	2.63
Mar 26	2.89
Mar 26	2.76
Feb 26	3.02
Feb 26	2.89
Feb 26	2.89
Feb 26	2.76
Jan 26	2.76
Jan 26	3.02
Jan 26	3.29
Jan 26	3.29
Jan 26	3.29
Dec 25	3.55
Dec 25	3.42
Dec 25	2.5
Dec 25	2.89
Nov 25	2.89
Nov 25	2.76
Nov 25	2.89
Nov 25	3.02
Oct 25	3.15
Oct 25	3.42
Oct 25	4.86
Oct 25	4.86
Oct 25	4.34
Sep 25	1.44
Sep 25	1.54
Sep 25	1.54
Sep 25	1.39
Aug 25	1.39
Aug 25	1.34
Aug 25	1.29
Aug 25	1.19
Aug 25	1.14
Jul 25	1.14
Jul 25	1.09
Jul 25	1.09
Jul 25	1.14
Jun 25	1.09
Jun 25	1.19
Jun 25	1.29
Jun 25	1.24
May 25	1.19
May 25	1.04
May 25	1.09
May 25	1.04
May 25	1.14
Apr 25	1.04
Apr 25	1.09
Apr 25	1.14
Apr 25	1.14
Mar 25	1.75
Mar 25	1.81
Mar 25	1.81
Mar 25	1.94
Feb 25	1.68
Feb 25	1.56
Feb 25	1.62
Feb 25	1.62
Jan 25	1.62
Jan 25	1.75
Jan 25	1.81
Jan 25	2.27
Jan 25	1.62
Dec 24	1.49
Dec 24	1.56
Dec 24	1.88
Dec 24	2.01
Nov 24	1.81
Nov 24	1.62
Nov 24	1.62
Nov 24	1.56
Nov 24	1.56
Oct 24	1.68

Price to Book

RAD.AX Price to Book by quarter
Period	Price to Book
Sep 26	0.57
Sep 26	0.57
Sep 26	0.64
Aug 26	0.64
Aug 26	0.71
Aug 26	0.78
Aug 26	0.85
Jul 26	0.99
Jul 26	1.35
Jul 26	1.42
Jul 26	1.35
Jul 26	1.42
Jun 26	1.35
Jun 26	1.42
Jun 26	1.42
Jun 26	1.42
May 26	1.42
May 26	1.49
May 26	1.49
May 26	1.35
May 26	1.35
Apr 26	1.42
Apr 26	1.42
Apr 26	1.56
Apr 26	1.49
Mar 26	1.09
Mar 26	1.09
Mar 26	1.2
Mar 26	1.14
Feb 26	1.25
Feb 26	1.2
Feb 26	1.2
Feb 26	1.14
Jan 26	1.14
Jan 26	1.25
Jan 26	1.36
Jan 26	1.36
Jan 26	1.36
Dec 25	1.47
Dec 25	1.42
Dec 25	1.03
Dec 25	1.2
Nov 25	1.2
Nov 25	1.14
Nov 25	1.2
Nov 25	1.25
Oct 25	1.31
Oct 25	1.42
Oct 25	2.02
Oct 25	2.02
Oct 25	1.8
Sep 25	0.22
Sep 25	0.23
Sep 25	0.23
Sep 25	0.21
Aug 25	0.21
Aug 25	0.2
Aug 25	0.19
Aug 25	0.18
Aug 25	0.17
Jul 25	0.17
Jul 25	0.16
Jul 25	0.16
Jul 25	0.17
Jun 25	0.16
Jun 25	0.18
Jun 25	0.19
Jun 25	0.19
May 25	0.18
May 25	0.16
May 25	0.16
May 25	0.16
May 25	0.17
Apr 25	0.16
Apr 25	0.16
Apr 25	0.17
Apr 25	0.17
Mar 25	0.36
Mar 25	0.37
Mar 25	0.37
Mar 25	0.4
Feb 25	0.35
Feb 25	0.32
Feb 25	0.33
Feb 25	0.33
Jan 25	0.33
Jan 25	0.36
Jan 25	0.37
Jan 25	0.47
Jan 25	0.33
Dec 24	0.31
Dec 24	0.32
Dec 24	0.39
Dec 24	0.41
Nov 24	0.37
Nov 24	0.33
Nov 24	0.33
Nov 24	0.32
Nov 24	0.32
Oct 24	0.35

No video analysis for this stock yet. Request one from our team.

News: RAD.AX

globenewswire.com · 17 Aug 2026

Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases

RAD 101 Phase 2b trial demonstrated 93% concordance with MRI across all evaluable lesions, meeting the Phase 2 trial's primary endpoint End-of-Phase 2 meeting with the U. S. FDA scheduled for October 1st, 2026; on track to be Phase 3 ready by year-end 2026 SYDNEY and MALVERN, Pa.

AI Analysis

Radiopharm Theranostics Limited

Video analysis: RAD.AX

News: RAD.AX

Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases

Similar companies